MA66915A1 - Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques - Google Patents

Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques

Info

Publication number
MA66915A1
MA66915A1 MA66915A MA66915A MA66915A1 MA 66915 A1 MA66915 A1 MA 66915A1 MA 66915 A MA66915 A MA 66915A MA 66915 A MA66915 A MA 66915A MA 66915 A1 MA66915 A1 MA 66915A1
Authority
MA
Morocco
Prior art keywords
diseases
lymph
treatment
fatty acid
acid compositions
Prior art date
Application number
MA66915A
Other languages
English (en)
French (fr)
Inventor
Richard Preston MASON
Richard Louis Dunbar
Original Assignee
Amarin Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ireland Limited filed Critical Amarin Pharmaceuticals Ireland Limited
Publication of MA66915A1 publication Critical patent/MA66915A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA66915A 2022-01-26 2023-01-26 Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques MA66915A1 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202263303365P 2022-01-26 2022-01-26
US202263303383P 2022-01-26 2022-01-26
US202263304042P 2022-01-28 2022-01-28
US202263334071P 2022-04-22 2022-04-22
US202263334065P 2022-04-22 2022-04-22
US202263340292P 2022-05-10 2022-05-10
US202263340304P 2022-05-10 2022-05-10
US202263342509P 2022-05-16 2022-05-16
US202263348908P 2022-06-03 2022-06-03
PCT/US2023/011651 WO2023146984A1 (en) 2022-01-26 2023-01-26 Lymph-releasing compositions of fatty acids and uses thereof for lymphatic incorporation and systemic disease treatment

Publications (1)

Publication Number Publication Date
MA66915A1 true MA66915A1 (fr) 2025-10-31

Family

ID=87472560

Family Applications (1)

Application Number Title Priority Date Filing Date
MA66915A MA66915A1 (fr) 2022-01-26 2023-01-26 Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques

Country Status (10)

Country Link
US (1) US20240165066A1 (enExample)
EP (1) EP4468884A4 (enExample)
JP (1) JP2025503961A (enExample)
KR (1) KR20240142470A (enExample)
AU (1) AU2023213684A1 (enExample)
CA (1) CA3248854A1 (enExample)
IL (1) IL314467A (enExample)
MA (1) MA66915A1 (enExample)
MX (1) MX2024009147A (enExample)
WO (1) WO2023146984A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377553B (es) * 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
WO2020245816A1 (en) 2019-06-03 2020-12-10 Migal Galilee Research Institute Ltd. 5,6-dihete lactone for treatment of microvascular dysfunction
GB202400712D0 (en) * 2024-01-18 2024-03-06 Northwood Consultants Ltd Anti-inflammatory composition and use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002221A1 (en) * 1986-09-29 1988-04-07 Kabivitrum Ab A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it
US20060165735A1 (en) * 2002-06-18 2006-07-27 Abril Jesus R Stable emulsions of oils in aqueous solutions and methods for producing same
US20080020033A1 (en) * 2003-12-02 2008-01-24 Hiroshi Kawashima Oil or Fat Compositions Containing Phospholipids and a Long-Chain Polyunsaturated Fatty Acid Supply Compound, and Food Using Same
US20110118351A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized Formulations of Fatty Acids

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) * 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
US6077525A (en) * 1998-04-10 2000-06-20 The George Washington University Use of conjugated linoleic acids
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20070042008A1 (en) * 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
EP1983977A4 (en) * 2006-01-31 2011-11-30 Martek Biosciences Corp OXYLIPINES FROM STEARIDONIC ACID AND GAMMA-LINOLIC ACID AND METHOD FOR THE PRODUCTION AND USE THEREOF
RU2470644C2 (ru) * 2006-09-05 2012-12-27 Кью.Пи. КОПЭРЕЙШН Стабильная жировая эмульсия (варианты), способ ее получения, эмульгирующий агент и способы стабилизации простагландина и капель жира
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
CA2894709C (en) * 2012-12-24 2022-08-09 Qualitas Health, Ltd. Eicosapentaenoic acid (epa) formulations
CA2974495C (en) * 2015-01-21 2023-05-23 Mochida Pharmaceutical Co., Ltd. .omega.-3 fatty acid self-emulsifying composition
KR102488648B1 (ko) * 2015-01-21 2023-01-12 모치다 세이야쿠 가부시키가이샤 ω3 지방산의 자기 유화 조성물
JP6783891B2 (ja) * 2019-04-10 2020-11-11 持田製薬株式会社 ω3脂肪酸の自己乳化組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002221A1 (en) * 1986-09-29 1988-04-07 Kabivitrum Ab A granulate containing gamma linolenic acid, eicosapentaenoic acid and/or docosahexaenoic acid, the method for its manufacturing, its use in edible products, and a tablet containing it
US20060165735A1 (en) * 2002-06-18 2006-07-27 Abril Jesus R Stable emulsions of oils in aqueous solutions and methods for producing same
US20080020033A1 (en) * 2003-12-02 2008-01-24 Hiroshi Kawashima Oil or Fat Compositions Containing Phospholipids and a Long-Chain Polyunsaturated Fatty Acid Supply Compound, and Food Using Same
US20110118351A1 (en) * 2009-11-10 2011-05-19 MyCell Holdings Limited Stabilized Formulations of Fatty Acids

Also Published As

Publication number Publication date
MX2024009147A (es) 2024-08-06
JP2025503961A (ja) 2025-02-06
EP4468884A4 (en) 2025-12-10
KR20240142470A (ko) 2024-09-30
AU2023213684A1 (en) 2024-08-15
US20240165066A1 (en) 2024-05-23
WO2023146984A1 (en) 2023-08-03
EP4468884A1 (en) 2024-12-04
CA3248854A1 (en) 2023-08-03
IL314467A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
MX2024009147A (es) Composiciones de acidos grasos liberadoras de linfa y usos de las mismas para la incorporacion linfatica y tratamiento de enfermedades sistemicas.
Ren et al. Primary open-angle glaucoma patients have reduced levels of blood docosahexaenoic and eicosapentaenoic acids
US6296861B1 (en) Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters
JP4828074B2 (ja) ポリエニルホスファチジルコリンを使用する皮膚の損傷の治療
FR2878747A1 (fr) Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
EA200701229A1 (ru) Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
AR021481A1 (es) Compuestos de 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas, uso para la preparacion de medicamentos, composiciones y kit que lo contiene
DK1419768T3 (da) Præparater med virkning til forebyggelse eller bedring af tilstande eller sygdomme forårsaget af hjernehypofunktion
Vilela et al. Aerobic and strength training induce changes in oxidative stress parameters and elicit modifications of various cellular components in skeletal muscle of aged rats
KR20000049016A (ko) 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는약제학적 제제
ES2255467T1 (es) Acidos grasos de cadena media, gliceridos y analogos como estimuladores de la eritropoyesis.
ATE424188T1 (de) Isotone fettemulsionen
Yorek The potential role of fatty acids in treating diabetic neuropathy
JPH07502491A (ja) 皮膚疾患の治療に対して静脈的に投与される薬剤を調整するためのエマルジョンの使用
Nicolai et al. Omega-3 and Omega-6 fatty acids act as inhibitors of the matrix metalloproteinase-2 and matrix metalloproteinase-9 activity
WO2021202680A3 (en) Krill oil composition enriched in lpc-dha and lpc-epa
WO2023205424A3 (en) Lipid compositions and methods for nucleic acid delivery
ATE138531T1 (de) Triglyceride-zusammensetzungen gegen fettbleichen
DK173547B1 (da) Salicylsyreholdigt middel til lokalbehandling af hudsygdomme med skæl inden for den humane og den veterinære medicin
CN1135218C (zh) 脂类混合物及其用途
RU2008108078A (ru) Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения
FR3130140B1 (fr) Agent de traitement capillaire avec effet de soin amélioré
MA53188A1 (fr) Composés aromatiques et leurs utilisations pharmaceutiques
DE59002738D1 (de) Kombinationspräparate enthaltend Chloramphenicol, Gentamicin und Nystatin als aktive Wirkstoffe zur topischen Behandlung entzündlicher Hauterkrankungen.
BRPI0505988A (pt) formulação cosmética e/ou dermtólogica e uso da mesma